Insmed (INSM) Total Non-Current Liabilities (2010 - 2026)
Insmed's (INSM) quarterly Total Non-Current Liabilities came in at $1.4 billion in Q1 2026, down 9.96% year-on-year from $1.5 billion in Q1 2025, and down 10.17% quarter-over-quarter from $1.5 billion in Q4 2025.
Insmed (INSM) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Insmed's Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $1.4 billion for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 9.96% year-over-year to $1.4 billion in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 9.96% decrease from a year earlier, with the FY2025 full-year figure at $1.5 billion, down 3.25% from the prior year.
- Total Non-Current Liabilities fell to $1.4 billion in Q1 2026 per INSM's latest filing, from $1.5 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.6 billion in Q2 2024 and bottomed at $953.5 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $1.5 billion (2025), against an average of $1.4 billion.
- Across the five-year window, Total Non-Current Liabilities surged 100.91% in 2022 and plunged 34.46% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $1.5 billion in 2022, then rose by 4.42% to $1.6 billion in 2023, then declined by 0.39% to $1.6 billion in 2024, then declined by 3.25% to $1.5 billion in 2025, then dropped by 10.17% to $1.4 billion in 2026.
- Per Business Quant, the three latest INSM Total Non-Current Liabilities figures stand at $1.4 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Insmed | 23.26 Bn | 22.03 Bn | 258.54 Mn | 1.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.37 Bn |
| Dec 31, 2025 | 1.52 Bn |
| Sep 30, 2025 | 1.41 Bn |
| Jun 30, 2025 | 1.05 Bn |
| Mar 31, 2025 | 1.52 Bn |
| Dec 31, 2024 | 1.57 Bn |
| Sep 30, 2024 | 1.57 Bn |
| Jun 30, 2024 | 1.60 Bn |
| Mar 31, 2024 | 1.55 Bn |
| Dec 31, 2023 | 1.58 Bn |
| Sep 30, 2023 | 1.54 Bn |
| Jun 30, 2023 | 1.59 Bn |
| Mar 31, 2023 | 1.56 Bn |
| Dec 31, 2022 | 1.51 Bn |
| Sep 30, 2022 | 1.02 Bn |
| Jun 30, 2022 | 953.51 Mn |
| Mar 31, 2022 | 967.32 Mn |
| Dec 31, 2021 | 757.37 Mn |
| Sep 30, 2021 | 783.05 Mn |
| Jun 30, 2021 | 685.92 Mn |